ASCO 2023

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

Ovarian function - Ovarian suppression not necessary in young patients?

Ribociclib improves iDFS

Young patients benefit from ovarian suppression

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

SOC of ovarian ablation confirmed in meta-analysis.

From PENELOPE-B to SURVIVE

Early follow-up shows clear benefit

De-escalation of CT for early BC

Ribociclib has arrived in the adjuvant setting

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

A challenge for clinical management

TILs are prognostic but not predictive in HER2+ EBC

Can we preserve our patients form chemotherapy?

First data with adjuvant ribociclib

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

More CDK4/6 options for EBC patients

Discussions on CDK4/6 inhibitors in EBC

Palbociclib after Palbociclib might not be the best option

Another proof of efficacy of immunotherapy in advanced TNBC

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

1/3 of patients with HER2+ in future without chemotherapy?

TILs in HER2+ disease - prognostic, but not enough to deescalate

10 years update on ShortHER

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

Practice changing or not quite yet?

My EBC highlights from ASCO23

Response adapted, chemotherapy-free option in HER2+ EBC

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

Eine Herausforderung für viele Patienten, wenig Doktoren

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

Palbociclib después de Palbociclib podría no ser la mejor opción

Eine Herausforderung für das klinische Management

I miei punti salienti di ASCO23

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

Von PENELOPE-B zur SURVIVE

Czy wystarczy, aby zmienić standardy?

NATALEE nicht überraschend aber überzeugend positiv

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Primele date cu ribociclib adjuvant

What is the optimal therapie sequence for HR+ MBC patients?

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

E-Health Applications in Oral Cancer Therapy

Continued OS benefit for Sacituzumab Govitecan

Molecular imaging for endocrine responsivness

The start of precision medicine in HR+ breast cancer

Updates on ADCs in metastatic breast cancer

Mises à jour sur les ADC dans le cancer du sein métastatique

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

The value of eHealth

Update ADC efficacy

CDK4/6i in first line and beyond & Biomarkers

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

AI for prediction in local prostate carcinoma

Part2: Important update on testosterone-recovery

PAPR-inhibitors: Patient-selection matters!

PEACE 1 - results and controversies

Over-staging of bone scan compared with PSMA PET/CT

Reassuring real-world data!

PRL-02: Intramuscular arbiraterone

Confirming results for PARPi in mCRPC

Intensified or de-intensified therapy in mHSPC

Metastasis-directed for prostate cancer

Part 1: Important update on testosterone-recovery

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

LuPARP combination study: LuPSMA and Olaparib in mCRPC

DEAR trial: real-world comparator analyses of ARIs

TALAPRO-2: Results and controversies

ARASEC: ADT + Daralutamide for mHSPC

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Intensifierad eller de-intensifierad behandling vid mHSPC?

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PARP-inhibitors: La selección de pacientes es importante

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

What is your preferred sequence in 1st line treatment and how you treat after progress?

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The beginning of a new era in urothelial cancer?!

New standard for MIBC

Targeted therapies in advanced urothelial cancer: The renaissance?!

Extent of lymphadenectomy in cystectomy

New SoC option for metastatic bladder cancer

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

FGFR inhibition

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

The efficacy of FGFR targeting

Update EV/Pembro, Avelumab Maintenance

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

The impact of microbiome and supplements on therapy efficacy

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Non ccRCC: how should we treat patients today?

New data non ccRCC

New standard for 2nd line RCC?

News from the adjuvant

1st Line therapy RCC: which combination to choose?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

Update and take home message of 1st Line mRCC

Long-term follow-up for IO/TKI in mRCC

IO rechallenge in mRCC

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

Confirmation of neoadjuvant immunotherapy

Perioperative treatment

A chemo-free preop. IO strategy?

More options in the perioperative setting

A new standard of care for operated patients with eGFRmut adenocarcinoma

Induction options in the perioperative setting

EGFR testing necessary in the adjuvant setting

Adjuvant IO in KRASm patients

Adjuvant and neoadjuvant strategies in resectable NSCLC

A new standard of care

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

Another neoadjuvant chemo/IO option

ADAURA - Discussion closed?

An imperfect analysis, but perfect results

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

OS benefit from EGFR receptor TKI

ADAURA - results and controversies

Role of periopertative IO confirmed

CheckMate 9LA: 4‑year clinical update

ADAURA- discussie gesloten?

Más opciones en el entorno perioperatorio

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Rolle der periopertativen IO bestätigt

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

TTF-treatment requires further studies

Update on KRASG12Cm treatment options - how to proceed?

Zorifertinib: an option when osimertinib is not available

Sotorasib: clear clinical benefit, but short follow-up time

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Does ADC + chemo + IO replace the existing concepts?

Stopping treatment is ok

ADC + ICI ± Pt-CT in patients with aNSCLC

IO in EGRF positive patients post TKI

LUNAR: TTF medical device shows OS-benefit, but more information needed

CORRELATE - a real world analysis

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

Treatment strategies in SCLC

More BiTEs, more possibilities

Hyperfractionated radiotherapy for SCLC

Can we incoporate biomarkers in SCLC treatment?

A positive trial with no impact

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

Stratégies de traitement dans le SCLC

Más BiTEs, más posibilidades

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immune checkpoint inhibitors in malignant mesothelioma

No practice-changing data in mesothelioma, other studies to await

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom